 3. Medical History and Concurrent Diseases: c. Prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways. d. Subjects with a history of interstitial lung disease. e. Other active malignancy requiring concurrent intervention. f. Subjects with previous malignancies except non-melanoma skin cancers, and the following in situ cancers: bladder, gastric, colon, endometrial, cervicaldysplasia, melanoma, or breast are excluded unless a complete remission was achieved at least 2 years prior to study entry AND no additional therapy is required during the study period. 